Van Gool, AlainCorrales, FernadoČolović, MirjanaKrstić, DanijelaOliver-Martos, BegonaMartínez-Cáceres, EvaJakasa, IvoneGajski, GoranBrun, VirginieKyriacou, KyriacosBurzynska-Pedziwiatr, IzabelaWozniak, Lucyna AlicjaNierkens, StephanPascual García, CésarKatrlik, JaroslavBojic-Trbojevic, ZankaVacek, JanLlorente, AliciaAntohe, FeliciaSuica, ViorelSuarez, Guillaumet’Kindt, RubenMartin, PetraPenque, DeborahMartins, Ines LancaBodoki, EdeIacob, Bogdan-CezarAydindogan, EdaTimur, SunaAllinson, JohnSutton, ChristopherLuider, TheoWittfooth, SaaraSammar, Marei2021-04-072021-04-072020-04Expert Rev Proteomics. 2020 Apr;17(4):257-273. doi: 10.1080/14789450.2020.1763174. Epub 2020 May 19.1478-9450http://hdl.handle.net/10400.18/7662The importance of biomarkers for pharmaceutical drug development and clinical diagnostics is more significant than ever in the current shift toward personalized medicine. Biomarkers have taken a central position either as companion markers to support drug development and patient selection, or as indicators aiming to detect the earliest perturbations indicative of disease, minimizing therapeutic intervention or even enabling disease reversal. Protein biomarkers are of particular interest given their central role in biochemical pathways. Hence, capabilities to analyze multiple protein biomarkers in one assay are highly interesting for biomedical research.engMultiplexingMass SpectrometryValidationBiomarkersGenómica Funcional e Estruturaljournal article10.1080/14789450.2020.1763174